- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Idenix Pharmaceuticals Inc
+ Add to WatchlistIDIX:US
4.1700 USD 0.2700 6.92%As of 20:10:00 ET on 05/17/2013.
Snapshot for Idenix Pharmaceuticals Inc (IDIX)
| Open: | 3.9000 | Day's Range: | 3.8100 - 4.1900 | Volume: | 3,052,935 |
|---|---|---|---|---|---|
| Previous Close: | 4.1700 | 52wk Range: | 3.2100 - 11.3000 | 1-Yr Rtn: | -48.39% |
Key Statistics for IDIX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.5300 |
| Est. EPS (USD) (12/2013) | -0.8500 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 558.61 |
| Shares Outstanding (M) | 133.96 |
| 30 Day Average Volume | 811,113 |
| Price/Book (mrq) | 2.9613 |
| Price/Sale (ttm) | 14.8625 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for IDIX
Company Profile & Key Executives for IDIX
Idenix Pharmaceuticals Inc. is a biopharmaceutical company that discovers and develops drugs for the treatment of human viral and other infectious diseases. The Company is focusing on the treatment of infections caused by hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV).
| Ronald C Renaud Jr "Ron"President/CEO | David N StandringExec VP/Chief Scientific Ofcr |
| Douglas MayersExec VP/Chief Medical Officer | Daniella BeckmanSenior VP/CFO/Treasurer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
IDIX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page